Our results demonstrate that, in CD8+ T-LGL leukemia, the CD16+/CD56- immunophenotype is associated with STAT3 mutations, identifying a more symptomatic and treatment requiring disease. This evidence concerns the gene NCAM1 and T-cell large granular lymphocyte leukemia.